Correctsequence Therapeutics Co., Ltd
Clinical trials sponsored by Correctsequence Therapeutics Co., Ltd, explained in plain language.
-
One-Time gene therapy aims to cure inherited blood disorder
⭐️ CURE ⭐️ ENROLLING_BY_INVITATIONThis early-stage study is testing a one-time treatment called CS-101 for people with beta-thalassemia, a serious inherited blood disorder. Doctors will collect a patient's own blood stem cells, edit a specific gene in the lab to boost healthy fetal hemoglobin production, and then…
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Mar 25, 2026 14:07 UTC
-
Gene-Edited cells: 15-Year watch for blood disorder breakthrough
Disease control ENROLLING_BY_INVITATIONThis study tracks patients for up to 15 years after they received an experimental gene therapy for beta-thalassemia, a serious inherited blood disorder. Researchers want to understand the long-term safety and effectiveness of the treatment, which uses the patient's own geneticall…
Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Apr 02, 2026 02:11 UTC
-
15-Year watch begins on pioneering gene therapy for blood disorder
Disease control ENROLLING_BY_INVITATIONThis study is tracking the long-term safety and effectiveness of a gene therapy called CS-101 for people with beta-thalassemia, a serious inherited blood disorder. It will follow 8 participants who received the therapy in a previous trial for up to 15 years. The main goals are to…
Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC